Vistagen Therapeutics, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended March 31, 2021; filed June 29, 2021. The filing is an annual report, not a report for calendar 2020 Q4. Vistagen is a clinical-stage biopharmaceutical company developing CNS drug candidates and had no approved products or product-sale revenue.
Business context and pipeline
- PH94B nasal spray: The lead program targets acute anxiety in adults with social anxiety disorder (SAD). The Phase 3 PALISADE-1 study began in late May 2021, after fiscal year-end. The FDA granted Fast Track designation for SAD.
- PH10 nasal spray: Exploratory Phase 2A development in major depressive disorder (MDD) was complete. Management planned to pursue Phase 2B development.
- AV-101: A prior Phase 2 MDD adjunctive trial did not meet its primary endpoint. The company was preparing a Phase 1B study of AV-101 with probenecid.
- Vistagen licensed PH94B to AffaMed for development and commercialization in Greater China, South Korea and Southeast Asia, while retaining rights elsewhere.
Financial performance and position
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $1.09 million, all sublicense revenue | None |
| Research and development expense | $12.48 million | $13.37 million |
| General and administrative expense | $6.55 million | $7.43 million |
| Net loss | $17.93 million | $20.77 million |
| Net loss attributable to common stockholders | $42.32 million | $22.04 million |
| Basic and diluted loss per common share | $0.49 | $0.50 |
| Cash used in operating activities | $12.07 million | $15.76 million |
- Revenue was the straight-line recognition of the $5.0 million AffaMed upfront payment; $3.91 million remained deferred at year-end. Revenue is not product sales and is not recurring.
- R&D spending shifted toward PH94B and PH10: related development expenses increased $5.2 million, while AV-101 study and other expenses fell $5.9 million, primarily following completion of the Elevate Study.
- Cash and cash equivalents were $103.11 million at March 31, 2021, versus $1.36 million a year earlier. Current assets were $104.12 million and current liabilities $4.19 million.
- Financing activities provided $114.10 million. The company reported about $119 million in net cash proceeds from financing and other transactions during FY2021, including $93.6 million net proceeds from its December public offering and $12.9 million from its August offering.
- Debt was limited at year-end: the insurance-premium notes and Paycheck Protection Program loan were repaid. Lease obligations were $3.72 million, primarily for the headquarters lease. Accrued Series B preferred dividends were $6.27 million.
- No meaningful operating margin is presented because the company had no product sales and incurred operating losses. The filing reports no material off-balance-sheet arrangements.
Material changes and unusual items
- FY2021 net loss improved by $2.84 million versus FY2020, while operating expenses declined $1.78 million and sublicense revenue contributed $1.09 million.
- Common-stockholder loss includes a $23.0 million noncash beneficial conversion feature charge on Series D preferred stock, recognized after stockholder approval of the share authorization amendment. It did not reduce cash or total stockholders’ equity.
- The December offering materially expanded funding but also increased dilution: it included 63 million common shares and convertible preferred securities. The Series D preferred was fully converted after year-end; common shares outstanding were 191.38 million as of June 28, 2021.
- At March 31, 2021, stockholders’ equity was $91.98 million, compared with a $5.73 million deficit one year earlier, largely reflecting financing proceeds.
Outlook, risks and contingencies
- Management said cash was sufficient to fund planned operations for well beyond the twelve months following issuance of the financial statements. It nevertheless expects continued operating losses and may seek additional financing.
- Planned priorities included the PH94B PALISADE Phase 3 program and exploratory Phase 2A studies, PH10 Phase 2B preparation, an AV-101/probenecid Phase 1B study, and nonclinical work. Management targeted PH10’s Phase 2B IND submission before year-end 2021 and trial initiation in the first half of 2022.
- AffaMed could provide up to $172 million in development, regulatory and sales milestones, plus royalties, but achievement and timing are uncertain. The company recognized only the upfront-payment revenue in FY2021.
- COVID-19 caused delays in delivery of PH94B and PH10 supplies and could disrupt manufacturing, enrollment, clinical timelines and access to capital. The company relies on third-party manufacturers and research organizations and has no long-term or redundant supply arrangements.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, ongoing capital needs and potential dilution, competitive therapies, intellectual-property challenges, reimbursement and pricing pressure, and dependence on a small workforce and external providers.
- Management identified material weaknesses in internal control over financial reporting: inadequate segregation of duties due to staffing limitations and accounting software that did not ensure controls over prior-period changes and an adequate audit trail. Remediation efforts began in April 2021. Disclosure controls were assessed as effective; the auditor did not attest to internal-control effectiveness.
- The independent auditor issued an unqualified opinion on the financial statements. The filing reports no legal proceedings.
Most important facts for investors to verify
- Progress, enrollment and results for PALISADE-1 and the broader PH94B Phase 3 program, including any effects from supply or pandemic disruptions.
- Actual cash burn and runway against the stated plans, and whether further equity issuance or collaboration funding is needed.
- PH10 regulatory and trial milestones, and the design and timing of the AV-101/probenecid Phase 1B study.
- AffaMed’s development progress and whether any contingent milestones or royalties become payable.
- Potential dilution from outstanding options, warrants and preferred securities; reconcile the reported share counts and subsequent conversions.
- The filing’s differing accumulated-deficit figures: narrative disclosures cite approximately $242.8 million, while the March 31, 2021 balance sheet reports $219.84 million. Verify the applicable definition and reconciliation.
- Remediation and testing of the identified financial-reporting control weaknesses.